• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

葡萄球菌激酶与链激酶在静脉血栓形成动物模型中的纤溶特性比较

Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis.

作者信息

Lijnen H R, Stassen J M, Vanlinthout I, Fukao H, Okada K, Matsuo O, Collen D

机构信息

Center for Thrombosis and Vascular Research, University of Leuven, Belgium.

出版信息

Thromb Haemost. 1991 Oct 1;66(4):468-73.

PMID:1796398
Abstract

The thrombolytic and pharmacokinetic properties of staphylokinase were compared with those of streptokinase in hamsters with a pulmonary embolus produced from human plasma or from hamster plasma, and in rabbits with a jugular vein blood clot produced from rabbit blood. In both models, a continuous intravenous infusion of staphylokinase and streptokinase over 60 min in hamsters or over 4 h in rabbits, induced dose-dependent progressive clot lysis in the absence of significant systemic activation of the fibrinolytic system. The results of thrombolytic potency (clot lysis at 30 min after the end of the infusion, in percent, versus dose administered, in mg/kg) were fitted with an exponentially transformed sigmoidal function (formula: see text) and the maximal percent clot lysis (c), the maximal rate of lysis (z = 1/4 ac.eb) and the dose at which the maximal rate of lysis is achieved (b) were determined. In hamsters with a pulmonary embolus produced from human plasma, streptokinase had a somewhat higher thrombolytic potency than staphylokinase, as revealed by a higher z value (2,100 +/- 1,100% lysis per mg/kg streptokinase administered versus 1,100 +/- 330% lysis per mg/kg for staphylokinase). In hamsters with a pulmonary embolus produced from hamster plasma, staphylokinase had a somewhat higher thrombolytic potency than streptokinase (z = 1,600 +/- 440 versus 1,200 +/- 370% lysis per mg/kg). Staphylokinase had a higher thrombolytic potency than streptokinase in rabbits,as revealed by a higher z-value (950 +/- 350% lysis per mg/kg staphylokinase administered versus 330 +/- 39% lysis per mg/kg for streptokinase) and a lower b-value (0.035 +/- 0.010 mg/kg staphylokinase versus 0.091 +/- 0.008 mg/kg for streptokinase.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

在由人血浆或仓鼠血浆产生肺栓塞的仓鼠以及由兔血产生颈静脉血栓的兔子中,对葡萄球菌激酶和链激酶的溶栓特性及药代动力学特性进行了比较。在这两种模型中,仓鼠连续60分钟或兔子连续4小时静脉输注葡萄球菌激酶和链激酶,在纤溶系统无显著全身激活的情况下,诱导剂量依赖性的渐进性血栓溶解。溶栓效力结果(输注结束后30分钟时的血栓溶解率,以百分比计,与给药剂量,以mg/kg计)用指数变换的S形函数拟合(公式:见正文),并确定最大血栓溶解百分比(c)、最大溶解速率(z = 1/4 ac·eb)以及达到最大溶解速率时的剂量(b)。在由人血浆产生肺栓塞的仓鼠中,链激酶的溶栓效力略高于葡萄球菌激酶,z值更高表明了这一点(每mg/kg链激酶给药的溶解率为2100±1100%,而每mg/kg葡萄球菌激酶给药的溶解率为1100±330%)。在由仓鼠血浆产生肺栓塞的仓鼠中,葡萄球菌激酶的溶栓效力略高于链激酶(每mg/kg的溶解率分别为1600±440%和1200±370%)。在兔子中,葡萄球菌激酶的溶栓效力高于链激酶,z值更高(每mg/kg葡萄球菌激酶给药的溶解率为950±350%,而每mg/kg链激酶给药的溶解率为330±39%)以及b值更低(葡萄球菌激酶为0.035±0.010 mg/kg,链激酶为0.091±0.008 mg/kg)表明了这一点。(摘要截断于250字)

相似文献

1
Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis.葡萄球菌激酶与链激酶在静脉血栓形成动物模型中的纤溶特性比较
Thromb Haemost. 1991 Oct 1;66(4):468-73.
2
Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model.
Thromb Haemost. 1991 Feb 12;65(2):174-80.
3
Differential inhibition with antifibrinolytic agents of staphylokinase and streptokinase induced clot lysis.抗纤溶药物对葡萄球菌激酶和链激酶诱导的凝块溶解的差异抑制作用。
Thromb Haemost. 1995 May;73(5):845-9.
4
Small animal thrombosis models for the evaluation of thrombolytic agents.用于评估溶栓药物的小动物血栓形成模型。
Circulation. 1991 Jun;83(6 Suppl):IV65-72.
5
Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons.狒狒体内链激酶和重组葡萄球菌激酶对动脉血栓和静脉血栓的免疫原性及溶栓特性比较
Circulation. 1993 Mar;87(3):996-1006. doi: 10.1161/01.cir.87.3.996.
6
[Thrombolysis by staphylokinase in rabbits with experimental pulmonary embolus].
Yao Xue Xue Bao. 1998 Nov;33(11):801-6.
7
Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models.组织型纤溶酶原激活剂、链激酶和葡萄球菌激酶对仓鼠模型脑缺血性梗死和肺血栓溶解的比较作用
Circulation. 1999;100(25):2541-6. doi: 10.1161/01.cir.100.25.2541.
8
Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.一种针对人纤维蛋白和尿激酶型纤溶酶原激活剂的双特异性单克隆抗体在体外和体内增强血凝块溶解作用。
Thromb Haemost. 1991 Dec 2;66(6):684-93.
9
Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.嵌合组织型和尿激酶型纤溶酶原激活剂的溶栓及药代动力学特性
Circulation. 1991 Sep;84(3):1216-34. doi: 10.1161/01.cir.84.3.1216.
10
Mechanism of action and thrombolytic potential of staphylokinase.葡萄球菌激酶的作用机制及溶栓潜力
Verh K Acad Geneeskd Belg. 1995;57(4):303-14.

引用本文的文献

1
Anti-stroke biologics: from recombinant proteins to stem cells and organoids.抗中风生物制剂:从重组蛋白到干细胞和类器官。
Stroke Vasc Neurol. 2024 Nov 5;9(5):467-480. doi: 10.1136/svn-2023-002883.
2
Plasminogen activation by staphylokinase enhances local spreading of S. aureus in skin infections.葡萄球菌激酶激活纤溶酶原可增强金黄色葡萄球菌在皮肤感染中的局部扩散。
BMC Microbiol. 2014 Dec 17;14:310. doi: 10.1186/s12866-014-0310-7.
3
Molecular analysis of human and canine Staphylococcus aureus strains reveals distinct extended-host-spectrum genotypes independent of their methicillin resistance.
对人源和犬源金黄色葡萄球菌菌株的分子分析揭示了不同的、具有广泛宿主谱的基因型,而与它们的耐甲氧西林特性无关。
Appl Environ Microbiol. 2013 Jan;79(2):655-62. doi: 10.1128/AEM.02704-12. Epub 2012 Nov 16.
4
Identification of a new exosite involved in catalytic turnover by the streptokinase-plasmin activator complex during human plasminogen activation.在人纤溶酶原激活过程中,鉴定链激酶 - 纤溶酶激活剂复合物催化周转所涉及的一个新的别构位点。
J Biol Chem. 2009 Nov 20;284(47):32642-50. doi: 10.1074/jbc.M109.046573. Epub 2009 Sep 30.
5
New thrombolytics, anticoagulants, and platelet antagonists: the future of clinical practice.新型溶栓剂、抗凝剂和血小板拮抗剂:临床实践的未来。
J Thromb Thrombolysis. 1999 Apr;7(2):195-220. doi: 10.1023/a:1008845822884.
6
Thrombolytic agents and anticoagulants.溶栓剂和抗凝剂。
Cardiovasc Drugs Ther. 1993 Nov;7(5):825-8. doi: 10.1007/BF00878937.
7
Novel thrombolytic agents.新型溶栓剂。
Cardiovasc Drugs Ther. 1994 Dec;8(6):801-11. doi: 10.1007/BF00877398.
8
Thrombolytic agents in development.正在研发的溶栓剂。
Drugs. 1995 Jul;50(1):29-42. doi: 10.2165/00003495-199550010-00003.
9
Advances in thrombolytic therapy.溶栓治疗的进展。
Cardiovasc Drugs Ther. 1992 Apr;6(2):111-24. doi: 10.1007/BF00054557.